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Summary. Escherichia coli is the main cause of urinary tract infections (UTI) in ambulatory patients, especially strains 
belonging to the B2 phylogenetic group and ST131 clonal group. Antibiotic treatment is usually administered empirically; 
however, it is not always effective due to bacterial multidrug resistance and the production of extended spectrum β-lactamases 
(ESBLs). The aim of this study was to characterize E. coli clinical isolates from patients with UTI in a community of the State 
of Guerrero, Mexico. From January to August 2014, 134 clinical isolates of E. coli were recovered. Strain identification and 
antibiotic susceptibility were performed using the Vitek automated system. Phylogenetic and O25b-ST13 groups were deter-
mined by multiple PCR. Identification of the blaCTX-M, blaTEM, and blaSHV genes was performed by conventional PCR. We found 
that over 50% of the isolates were resistant to betalactams and quinolones, while 0 to 33% were resistant to aminoglycosides 
and nitrofurans, and 56.49% of the strains were ESBL producers. B2 phylogenetic group was the most predominant (43%) 
compared to the other groups. The prevalence of bla genes was: blaCTX-M 64.3%, blaSHV 41.4%, and blaTEM 54.3%. These results 
show a high percentage (55%) of multidrug-resistant strains isolated from UTI patients from the community in the city of 
Chilpancingo, Guerrero, Mexico. [Int Microbiol 19(4): 209-215 (2016)]
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Introduction
Urinary tract infections (UTIs) are defined by the presence of 
bacterial pathogens in the urinary tract. They are the second 
most prevalent infectious disease, comprising around one 
fourth of all infections [13]. In Mexico, they are the first cause 
of medical outpatient consultation of women in reproductive 
age, and in 2010 they were the third cause of morbidity [4]. 
UTIs are classified according to the site of infection, in un-
complicated and complicated [25]. In most cases, uncompli-
cated UTIs are treated effectively by empirical antibiotic 
therapy, without performing urine culture unless the empirical 
therapy fails. This empirical therapy, coupled with the high 
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rate of infections per year worldwide, and the indiscriminate 
use of antibiotics, has led to an increase in antibiotic resis-
tance in UTI-causing bacteria [1]. Thus, treatments have be-
come more complex, since there has been an increase in anti-
biotic resistance along with the occurrence of extended-spec-
trum β-lactamases (ESBLs) [21].
ESBLs are plasmid-encoded enzymes produced by many 
Gram-negative bacteria. They confer resistance to penicil-
lins, broad-spectrum cephalosporins (e.g., cefotaxime, cef-
triaxone, ceftazidime) and monobactams (e.g., aztreonam), 
but not to cephamycins (e.g., cefoxitin and cefotetan) and 
carbapenems (e.g., imipenem, meropenem, and ertapenem). 
They are usually located on large plasmids, which also carry 
genes for resistance to other antibiotics, including fluoroquino-
lones, aminoglycosides, and cotrimoxazole. These β-lacta-
mases, unlike AmpC β-lactamases, are inhibited by clavu-
lanic acid, tazobactam or sulbactam [19,29]. ESBL-produc-
ing strains also show co-resistance to aminoglycosides, fluo-
roquinolones, tetracyclines, nitrofurantoin, and trimetho-
prim-sulfamethoxazole [30]. The most common β-lact mases 
are the TEM and SHV types, which are mainly expressed in 
Escherichia coli and Klebsiella pneumoniae, respectively, 
and also the CTX-M, which was described later [3].
Escherichia coli is the leading cause of urinary tract in-
fections, it being responsible for 75−90% of UTIs in ambu-
latory patients [24]. This bacterium has been classified into 
seven main phylogenetic groups (A, B1, B2, C, D, E, and F), 
and one Escherichia cryptic clade I, based on the combina-
tion of four genetic markers: arpA, chuA, yjaA, and the DNA 
fragment TspE4.C2 [7]. Uropathogenic strains usually be-
long to groups B2 and to a lesser extent to group D, whereas 
commensal strains belong to groups A and B1 [2,27]. Among 
B2 pathogenic strains, E. coli sequence type 131 (ST131) is 
considered an emerging important pathogen. Strains belong-
ing to this group are resistant not only to most β-lactam an-
tibiotics, but also to aminoglycosides and fluoroquinolones 
[17]. Most ST131 strains belong to the O25:H4 serotype, 
they having the specific O25b type. However, ST131 strains 
with serotype O16:H5 have been recently identified, as well 
as some others that are non typeable for O and H antigens 
[11,20].
The aim of this work was to analyze a total of 134 E. coli 
clinical isolates from ambulatory patients with UTI from the 
community in the city of Chilpancingo, Guerrero, Mexico in 
order to determine their antibiotic susceptibility, ESBLs 
production and phylogenetic group.
Material and methods
Escherichia coli isolates and antibiotic susceptibility testing. 
Clinical urine samples from 131 ambulatory patients from the ISSSTE clinic 
in Chilpancingo, Guerrero, Mexico where analyzed. Samples were collected 
from January to August of 2014 and only one isolate per patient was exam-
ined. Identification of isolates and antimicrobial susceptibility testing was 
performed by Vitek automated system. Antibiotics assayed were: ampicillin, 
ampicillin/sulbactam, cefazolin, ceftriaxone, cefepime, aztreonam, amikacin, 
gentamicin, tobramycin, ciprofloxacin, moxifloxacin, nitrofurantoin, and tri-
methoprim/sulfamethoxazole. Isolates resistant to antibiotics of three or more 
different classes were classified as multidrug-resistant (MDR).
ESBLs production. ESBLs production was confirmed by the double-
disk synergy test (DDST) following the CLSI guidelines [Clinical and Labo-
ratory Standards Institute (CLSI). Performance standards for antimicrobial 
susceptibility testing, 16th informational supplements. CLSI Document M2-
A9, Wayne PA: 2006]. Disks containing ceftazidime (30 µg) or cefotaxime 
(30 µg) with or without 10 µg clavulanic acid were used. The plates were 
incubated at 37 °C for 18 h. Escherichia coli strain ATCC 25922 was used as 
negative control, and K. pneumoniae strain ATCC 700603 was used as posi-
tive control.
Conventional phylogenetic grouping. Extraction of total bacterial 
DNA from isolated E. coli colonies was performed by heat shock, boiling 2 
to 3 colonies resuspended in 100 µl of distilled water for 5 min. Samples were 
cooled in ice for 5 min, boiled again, and centrifuged at 10,000 rpm for 2 min. 
The supernatant was recovered and stored at −20 °C until use. Assignment of 
E. coli phylogenetic groups was performed using the quadruplex phylo-group 
assignment PCR assay described by Clermont et al. [7] using primers for 
genes arpA, chuA and yjaA, and the TspE4.C2 DNA fragment. PCR was per-
formed in a final volume of 20 µl using 2.5 U of Taq polymerase, 2 mM 
dNTP’s, 25 mM MgCl2, 2 µl 10X buffer, 20 pmol of each primer, and 200 ng 
of DNA. The conditions used were: 5 min at 94 °C (1 cycle), 30 s at 94 °C, 
30 s at 55 °C, 30 s at 72 °C (30 cycles), 7 min at 72 °C. The amplicons were 
analyzed by 2% agarose gel electrophoresis. 
The detection of O25b/ST131 clonal group was done only with isolates 
belonging to the B2 phylogenetic group by multiplex PCR using primers 
O25pabBspe.F (5´-TCCAGCAGGTGCTGGATCGT-3´) and O25pabBspe.R 
(5´-GCGAAATTTTTCGCCGTACTGT-3´) [8] , and rfb1bis.f (5´-ATACC-
GACGACGCCGATC-3´) and rfbO25b.r (5´-TGCTATTCATTATGCG-
CAGC-3´) [9]. PCR was performed as follows: 2 min at 94 °C (1 cycle), 30 s 
at 94 °C, 10 s at 60 °C, 30 s at 72 °C (30 cycles), 2 min at 72 °C. The ampli-
cons were analyzed by 2% agarose gel electrophoresis.
Identification of bla genes. The identification of bla genes was per-
formed by PCR using specific primers for TEM, SHV and CTX-M types: 
TEMF (5´-CCTTCCTGTTTTTGCTCACCCA-3´), TEMR (5´-TACGATAC-
GGGAGGGCTTAC-3´) [16], SHVF (5´-ATGCGTTATATTCGCCTGTG-3´), 
SHVR (5´-TTAGCGTTGCCAGTGCTCGAT-3´) [18] CTX-M/F´ (5´-TTT-
GCGATGTGCAGTACCAGTAA-3´), and CTX-M/R´ (5´-CGATATCGTTG 
GTGGTGCCATA-3´) [12]. PCR was performed in a final volume of 25 µl 
using 5 U of Taq polymerase, 10 mM dNTPs, 25 mM MgCl2, 10X buffer, 10 
pmol of each primer and 5 µl of DNA. The amplicons were analyzed by 2% 
agarose gel electrophoresis. Escherichia coli strain ATCC 25922 was used as 
negative control, ESBLs-producing E. coli strains carrying genes SHV-2, 
TEM-1 and CTX-M-15 were used as positive controls.
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Conjugation experiments and plasmid isolation. A resistance 
transfer experiment using a conjugation assay based on the method de-
scribed by Miller (1992) was performed for 5 strains carrying ESBLs 
genes. Sodium azide-resistant E. coli J53 was used as the recipient strain. 
Transconjugants were selected in selective media containing sodium azide 
(150 µg/ml) (Sigma) plus ampicillin (AMP) or ceftazidime (CAZ), and rep-
licated afterwards in media M9 and MM. Plasmid DNA was extracted from 
clinical isolates and transconjugants by the method described by Kieser 
[15]. Purification of the 6-kb plasmids was performed with the Zymo Plas-
mid Miniprep kit according to the manufacturer’s instructions. DNA was 
visualized after electrophoresis in 1% agarose gels stained with ethidium 
bromide.
Minimum inhibitory concentration (MIC). The isolates that were 
positive for ESBLs production were confirmed by the MIC reduction test 
using the broth dilution method according to the CLSI guidelines. The rang-
es of concentrations tested were 256–0.03 µg/ml for CAZ, and 256–0.015 
µg/ml for CTX in Mueller-Hinton broth. Cut points: CTX-S (sensitive): ≤8; 
I (intermediate): 10–32; R (resistant): ≥64; CAZ-S: ≤8; I: 16; R: ≥32. Plates 
were incubated at 35 °C for 18 h. The E. coli ATCC 25922 strain was used 
as a control to validate susceptibility tests.
Statistical analysis. All statistical analyses were performed using the 
Stata-Transfer V.12.0 software. Correlation between ESBLs production and 
antibiotic susceptibility was analyzed with the Chi-squared test. Phylogenetic 
Table 1. Correlation between antibiotic susceptibility patterns and ESBL production of isolated Escherichia coli strains
Antibiotic resistance ESBL–   n (%) ESBL+  n (%) Total   % P value
Ampicillin Susceptible 19 (15.2) 0 (0) 15.2 < 0.001*
Resistant 36 (28.8) 70 (56) 84.8
Ampicillin/Sulbactam Susceptible 21 (16.8) 21 (16.8) 33.6 0.522
Resistant 34 (27.2) 49 (39.2) 66.4
Cefazolin Susceptible 48 (38.4) 1 (0.8) 39.2 <0.001*
Resistant 7 (5.6) 69 (55.2) 60.8
Ceftriaxone Susceptible 53 (42.4) 1 (0.8) 43.2 <0.001*
Resistant 2 (1.6) 69 (55.2) 56.8
Cefepime Susceptible 52 (41.6) 1 (0.8) 42.4 <0.001*
Resistant 3 (2.4) 69 (55.2) 57.6
Aztreonam Susceptible 52 (41.6) 2 (1.6) 43.2 <0.001*
Resistant 3 (2.4) 68 (54.4) 56.8
Gentamicin Susceptible 48 (38.4) 36 (28.8) 67.2 <0.001*
Resistant 7 (5.6) 34 (27.2) 32.8
Tobramycin Susceptible 51 (40.8) 34 (27.2) 68 <0.001*
Resistant 4 (3.2) 36 (28.8) 32
Ciprofloxacin Susceptible 41 (32.8) 14 (11.2) 44 <0.001*
Resistant 14 (11.2) 56 (44.8) 56
Moxifloxacin Susceptible 42 (33.6) 14 (11.2) 44.8 <0.001*
Resistant 13 (10.4) 56 (44.8) 55.2
Nitrofurantoin Susceptible 49 (39.2) 64 (51.2) 90.4 0.634
Resistant 6 (4.8) 6 (4.8) 9.6
Trimethoprim/Sulfamethoxazole Susceptible 26 (20.8) 17 (13.6) 34.4 0.008*
Resistant 29 (23.2) 53 (42.4) 65.6
Multiresistant No MDR 42 (33.6) 14 (11.2) 44.8 <0.001*
MDR 13 (10.4) 56 (44.8) 55.2
* P value < 0.05, statistically significant.
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groups and bla genes were compared using Fisher’s exact test. All P values 
> 0.05 were considered statistically significant.
Results
Identification and susceptibility patterns. Of 
the 131 isolates tested, 4 were identified as Escherichia fergu-
sonii and 2 as E. albertii, leaving us with 125 E. coli strains. 
Of the 125 strains isolated, 84.8% were resistant to ampicil-
lin, 66.4% to ampicillin/sulbactam, 60.8% to cefazolin, 
56.8% to ceftriaxone, 57.6% to cefepime, 56.8% to aztreo-
nam, 32.8% to gentamycin, 32% to tobramycin, 56% to cip-
rofloxacin, 55.2% to moxifloxacin, and 65.6% to trime-
thoprim/sulfamethoxazole. Note that all of the isolates were 
sensitive to amikacin and carbapenems, while 90.4% were 
sensitive to nitrofurantoin. More than half of the isolates 
(55.2%) were classified as MDR, since they were resistant to 
3 or more classes of antibiotics. To determine if the isolated 
strains produced ESBLs, a DDST assay was performed. Of 
the 125 isolated strains, 70 (56%) were positive for ESBLs 
production. The correlation between susceptibility rates of 
the isolated strains and ESBLs production are shown in Table 
1. MDR is related to ESBLs production, obtaining statisti-
cally significant P values.
 
Phylogenetic grouping. Of the 125 clinical isolates 
,12.8% belonged to group A, 6.4% to group B1, 43.2% to 
group B2, 10.4% to group C, 10.4% to group D, 2.4% to 
group E, 7.2% to group F, and 7.2% to clade I, group B2 being 
the most prevalent. We then analyzed strains in group B2 to 
determine if they belonged to the O25b-ST131 group. PCR 
results showed amplified products with both pairs of primers 
in 37% of the clinical isolates, meaning that they belonged to 
the O25b-ST131 group; 59.3% showed products only with 
primers O25pabBspe, meaning that they belonged to the se-
quence type ST131, and 3.7% were positive only for sero-
group O25b.
 
ESBLs identification and horizontal transfer. 
As shown in Table 2, 52.8% of ESBLs-producing strains be-
longed to group B2, while the rest were distributed among the 
other groups, except group E. The PCR was performed for the 
70 positive strains to detect the bla gene blaCTX-M. This gene 
was present in 64.3% of the isolated strains. The bla genes 
blaTEM and blaSHV were also detected, they being present in 
54.3% and 41.4%, respectively. After identifying the bla 
genes, we correlated them with the phylogenetic groups (Ta-
ble 3). Our results showed that none of the two strains identi-
fied as B1 were positive for blaCTX-M, while it was the most 
prevalent in strains from group B2. Group B2 also had the 
most strains with blaTEM and blaSHV. Of the strains belonging 
to group O25b-ST131, 75% contained the blaCTX-M gene.
As most ESBLs genes have been shown to be encoded in 
plasmids [26], we performed conjugation assays with 5 ES-
BL-producing strains. As shown in Table 4, two strains (2890 
and 3361) could transfer large-sized plasmids, although strain 
2890 only transferred one, while the rest of the strains trans-
Table 2. Correlation between Escherichia coli phylogenetic groups and 
ESBLs production
Phylogenetic group
(n = 125) *
ESBL
Positive [n (%)] Negative [n (%)] Total (n)
A 8 (11.4) 8 (14.5) 16
B1 2 (2.8) 6 (10.9) 8
B2 37 (52.8) 17 (30.9) 54
C 6 (8.5) 7 (12.7) 13
D 5 (7.1) 8 (14.5) 13
E 0 (0) 3 (5.4) 3
F 7 (10.0) 2 (3.6) 9
Clade I 5 (7.1) 4 (7.2) 9
Total 70 (100) 55 (100) 125
* P value = 0.042, calculated with Fisher’s exact test.
Table 3. Escherichia coli phylogenetic groups and bla genes prevalence
Phylogenetic group TEMa  [n (%)] SHVb [n (%)] CTX-M* [n (%)]
A 4 (10.5) 4 (13.8) 4 (8.9)
B1 1 (2.6) 2 (6.9) 0
B2 19 (50) 12 (41.4) 27 (60)
C 3 (7.9) 1 (3.4) 6 (13.3)
D 4 (10.5) 2 (6.9) 4 (8.9)
F 5 (13.2) 6 (20.7) 1 (2.2)
Clade I 2 (5.3) 2 (6.9) 3 (6.7)
Total 38 (100) 29 (100) 45 (100)
*P value = 0.005 (statistically significant), calculated with Fisher’s exact 
test.
a (P = 0.513), b (P = 1.00).
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ferred only a 6-kb plasmid. To determine which bla genes 
were transferred, we performed PCR with purified plasmids 
from the transconjugants. Three strains received all the bla 
genes from the donor strains (T3332, T2806 and T3361), 
while the other two did not receive the blaCTX-M gene. The two 
strains that did not receive the blaCTX-M gene were sensitive to 
CAZ and CTX, suggesting that CTX-M should be the func-
tional ESBLs.
Discussion 
Escherichia coli is the most common cause of uncomplicated 
and community acquired UTIs. Our results showed that mul-
tidrug resistance strains of E. coli were present in UTI pa-
tients from Chilpacingo, Guerrero, and that those strains be-
longed mainly to the phylogenetic group B2, specifically the 
sequence type ST131, which has been identified as the main 
etiological agent of community-acquired UTI, with resistance 
conferred by CTX-M-type β-lactamase enzymes [10]. Of the 
94.54% of strains positive for ST131, only 36.36% belonged 
to serogroup O25b. The group O25b-ST131 is well recog-
nized as an international pandemic clonal group [28], and in 
2011 was identified in Mexico City [23] and Chilpancingo, 
Guerrero [22]. The strains that were positive for ST131 but 
negative for O25b might belong to serogroup O16, which has 
also been associated with the clonal group B2-ST131, and can 
also be detected with the Clermont pabB PCR test, because 
the O16-ST131 group carries the same pabB allele (pabB74) 
[20].
We also observed that 56.7% of the isolated strains were 
MDR, and of these, 45.5% produced ESBLs. However, to de-
termine which ESBLs-type enzyme is involved in this pheno-
type, it would be necessary to sequence all the bla genes iden-
tified, since this is essential to discriminate between the non-
ESBLs enzymes (e.g., TEM-1 or SHV-1) from the different 
variants of TEM and SHV ESBLs (e.g. TEM-3, SHV-2, etc.) 
[3], especially in the case of the transconjugants that, despite 
being positive for TEM and SHV bla genes, were sensitive to 
CAZ and CTX.
Consistently with the fact that the group O25b-ST131 has 
been associated with the presence of the ESBLs type CTX-
M-15, it appears to be a correlation between O25b-ST131 
strains (36.36%) and the presence of the CTX-M enzyme 
(38.2%). However, the sequencing of the blaCTX-M genes is 
necessary to determine that they effectively belong to the 
CTX-M-15 type. Note that the prevalence of the CTX-M-type 
ESBLs reported in this work is the lowest found in this region 
since 2003, when Castro et al. [5] found this gene with a prev-
alence of 43%, and by 2010 it had increased to 50% [6].
Regarding antibiotic resistance, our results are consistent 
with previous reports that show that Mexican strains have the 
highest rates of ampicillin-resistant bacteria (almost 80%), 
and trimethoprim (61%) [14]. In fact, 85% of the strains we 
Table 4. Genotypic and phenotypic characteristics of Escherichia coli isolates and their transconjugants
Strain Phylog. group Plasmid (kb) ESBL
MIC (µg/ml) Trans-
conjugant Plasmid (kb) ESBL
MIC (µg/ml)
CAZ CTX CAZ CTX









2806 B2 110, 6 CTX-M, TEM >256 >256 T2806 6
CTX-M, 
TEM 128 >256




128 >256 T2136 6 SHV, TEM 0.06 0.25




>256 >256 T2890 90 SHV, TEM 0.5 0.25
3361 D 130, 100 CTX-M,SHV >256 >256 T3361 130, 100
CTX-M,
SHV >256 >256
MIC: minimum inhibitory concentration. CAZ: ceftazidime. CTX: cefotaxime.
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analyzed were ampicillin resistant and 68% were trime-
thoprim/sulfamethoxazole resistant. ESBL-producing strains 
are known to be resistant to all cephalosporins, broad-spec-
trum penicillins and aztreonam, as were our isolated strains, 
which showed between 57% and 66% resistance to these an-
tibiotics. In addition, resistance to trimethoprim/sulfamethox-
azole and aminoglycosides is generally transferred in the 
same plasmid, which makes therapeutic options limited. This 
seems to be the case for trimethoprim/sulfamethoxazole, for 
which we detected a high percentage of resistant strains, of 
which 43.3% were ESBLs positive. However, the resistance 
to aminoglycosides was low, ranging from around 30% for 
gentamycin and tobramycin to 0% for amikacin. These results 
indicate that in Chilpancingo, Guerrero, Mexico, it is still pos-
sible to use aminoglycosides to treat UTIs (especially amika-
cin), along with nitrofurantoin, for which only 10% of our 
strains were resistant.
Note that, in 3 of 5 transconjugants, only a 6-kb plasmid 
was transferred, not the high molecular weight plasmids. Ap-
parently, 2 of these 3 plasmids were R-plasmids, since they 
transferred bla genes, and the recipient strains became CAZ 
and CTX resistant. Although the third plasmid transferred the 
blaTEM and blaSHV genes, it did not transfer blaCTX-M, and thus 
the recipient strain was not resistant. Actually, the blaCTX-M 
gene was the only one that was not transferred in 100% of the 
cases, it being present in only 60% of the transconjugants. 
However, our results suggest that in our study population the 
CTX-M-type was the main ESBL. 
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